Cargando…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-...
Ejemplares similares
-
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
por: Xu, Jiuyang, et al.
Publicado: (2020) -
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
por: Huang, Chaolin, et al.
Publicado: (2023) -
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis
por: Zhang, Xueyang, et al.
Publicado: (2022) -
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
por: Liu, Zhibo, et al.
Publicado: (2021) -
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study
por: Huang, Lixue, et al.
Publicado: (2022)